DURECT Corporation - Special Call Transcript
Greetings. Welcome to KOL Call on DUR-928 Phase IIa Alcoholic Hepatitis Study Results, hosted by DURECT. (Operator Instructions) As a reminder, this call is being recorded.
I'll now turn the conference over to Jim Brown, President and CEO of DURECT. Mr. Brown, you may now begin.
Thank you. Well, hello, everyone, and welcome to our webcast and the DUR-928 that we're sending here from The Liver Meeting, which is just wrapping up here in Boston. Today, we announced positive results from our Phase IIa clinical trial of DUR-928 in alcoholic hepatitis patients. These results were given in a late-breaking presentation at the meeting this morning by Dr. Tarek Hassanein. Additionally, these studies' results were selected for inclusion in the Best of The Liver Meeting summary slide presentation in the alcoholic-related liver disease category. They were also summarized in the press release that can be found on our website, along with a copy of the slides that Dr. Hassanein and I will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |